1546PASSESSMENT OF OLDER PATIENTS WITH CANCER: EDMONTON FRAIL SCALE (EFS) AS A PREDICTOR OF ADVERSE OUTCOMES IN A COHORT OF OLDER PATIENTS UNDERGOING SYSTEMIC THERAPY
Abstract Aim: Older cancer patients (pts) are at risk of toxicity from systemic therapy (ST). The EFS is a geriatric tool assessing frailty covering: Cognition, Health, Independence, Performance, Social, Medications, Nutrition, Mood, and Continence. It is unknown if the EFS can predict toxicity in p...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2014-09, Vol.25 (suppl_4), p.iv538-iv538 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | iv538 |
|---|---|
| container_issue | suppl_4 |
| container_start_page | iv538 |
| container_title | Annals of oncology |
| container_volume | 25 |
| creator | O'Brien, M.M. Pfeiffer, E.M. Yen, D. Keenan, L. McHugh, J. Doyle, P. Doherty, M. O'Reilly, A. Hennessy, B. Williams, D. Horgan, A.M. Breathnach, O.S. Grogan, W.M. Morris, P. |
| description | Abstract
Aim: Older cancer patients (pts) are at risk of toxicity from systemic therapy (ST). The EFS is a geriatric tool assessing frailty covering: Cognition, Health, Independence, Performance, Social, Medications, Nutrition, Mood, and Continence. It is unknown if the EFS can predict toxicity in pts who have already been selected for ST. Prospectively we examined the EFS as a predictor of adverse outcomes in older pts undergoing ST.
Methods: Candidates seen by a Medical Oncologist and deemed appropriate for ST ≥65years, starting new ST were included. EFS, demographics, diagnosis, ECOG performance status (PS) and adverse events using the NCI CTCAE v4.03 were assessed. The association between EFS and toxicity was examined during one treatment cycle using Pearson's correlation coefficient (r).
Results: From Feb-April 2014, 24 pts were included (table), median age 72 years (65–92). EFS results were; No frailty 10 (42%), Apparently vulnerable 8 (33%), Mild frailty 4 (17%), Moderate frailty 1 (4%) and Severe frailty 1 (4%). Many were of good PS (54% had ECOG 1). All toxicities were recorded with most common non-lab toxicities being fatigue 12 (50%) and pain 8 (33%), all ≤grade III. The most common lab toxicities were Hb and Alk Phos. During ST there were 3 (13%) admissions, 6 (25%) had treatments held or dose adjustments and 1 death occurred. Age and ECOG were significantly correlated (r=0.43, p = |
| doi_str_mv | 10.1093/annonc/mdu356.66 |
| format | Article |
| fullrecord | <record><control><sourceid>oup</sourceid><recordid>TN_cdi_oup_primary_10_1093_annonc_mdu356_66</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdu356.66</oup_id><sourcerecordid>10.1093/annonc/mdu356.66</sourcerecordid><originalsourceid>FETCH-oup_primary_10_1093_annonc_mdu356_663</originalsourceid><addsrcrecordid>eNqVkE1LxDAYhIMoWD_uHt-jIt1Ntm203kL6dhtok5JklT2F4gcobnfZsgf_kL_TLuvRi6dhhmEGHkKuGJ0wmifTru_X_fN09bJLMj7h_IhELON5fE9Tdkwims-S-C5L0lNyNgwflFKez_KIfLMs5a1wDp1rUHswJZi6QAut8GoMHDwpX4EUWqJ9ACwao73RUFqhanBS1AjXWLobEA4EtBYLJb2x-yFRPKJ1CGbhpWnQgdJjRZrK2L-OFnq0c6P0HNzSeWyUBF-hFe3ygpy8dZ_D6-WvnpPbEr2s4vVuEzbb91W3_QqMhj2KcEARDigC58n_2j-4cFue</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>1546PASSESSMENT OF OLDER PATIENTS WITH CANCER: EDMONTON FRAIL SCALE (EFS) AS A PREDICTOR OF ADVERSE OUTCOMES IN A COHORT OF OLDER PATIENTS UNDERGOING SYSTEMIC THERAPY</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>O'Brien, M.M. ; Pfeiffer, E.M. ; Yen, D. ; Keenan, L. ; McHugh, J. ; Doyle, P. ; Doherty, M. ; O'Reilly, A. ; Hennessy, B. ; Williams, D. ; Horgan, A.M. ; Breathnach, O.S. ; Grogan, W.M. ; Morris, P.</creator><creatorcontrib>O'Brien, M.M. ; Pfeiffer, E.M. ; Yen, D. ; Keenan, L. ; McHugh, J. ; Doyle, P. ; Doherty, M. ; O'Reilly, A. ; Hennessy, B. ; Williams, D. ; Horgan, A.M. ; Breathnach, O.S. ; Grogan, W.M. ; Morris, P.</creatorcontrib><description>Abstract
Aim: Older cancer patients (pts) are at risk of toxicity from systemic therapy (ST). The EFS is a geriatric tool assessing frailty covering: Cognition, Health, Independence, Performance, Social, Medications, Nutrition, Mood, and Continence. It is unknown if the EFS can predict toxicity in pts who have already been selected for ST. Prospectively we examined the EFS as a predictor of adverse outcomes in older pts undergoing ST.
Methods: Candidates seen by a Medical Oncologist and deemed appropriate for ST ≥65years, starting new ST were included. EFS, demographics, diagnosis, ECOG performance status (PS) and adverse events using the NCI CTCAE v4.03 were assessed. The association between EFS and toxicity was examined during one treatment cycle using Pearson's correlation coefficient (r).
Results: From Feb-April 2014, 24 pts were included (table), median age 72 years (65–92). EFS results were; No frailty 10 (42%), Apparently vulnerable 8 (33%), Mild frailty 4 (17%), Moderate frailty 1 (4%) and Severe frailty 1 (4%). Many were of good PS (54% had ECOG 1). All toxicities were recorded with most common non-lab toxicities being fatigue 12 (50%) and pain 8 (33%), all ≤grade III. The most common lab toxicities were Hb and Alk Phos. During ST there were 3 (13%) admissions, 6 (25%) had treatments held or dose adjustments and 1 death occurred. Age and ECOG were significantly correlated (r=0.43, p = <0.04). Age was not associated with toxicity events (r=0.19, p < 0.37). ECOG PS was not associated with total number of toxicities (r=-0.05, p < 0.8). A moderate association between EFS and number of toxicity events was seen (r=0.32), but did not reach statistical significance (p < 0.14). Updated results including toxicity on subsequent ST cycles from an expanded cohort will be presented.
Patient CharacteristicsN%SexMale1042Female1458Marital StatusMarried1042Widowed833Single417Divorced / separated28Work StatusRetired2292Part-time employed14Other14Cancer DiagnosisColorectal625Breast625Other GI313Lung313Genitourinary28Others417StageI-III1250IV1146N/A (Brain)14
Conclusions: Preliminary results suggest elevated EFS score is associated with toxicities during the first cycle of ST. Quantifying frailty could aid formation of a predictive model for adverse events in the geriatric population.
Disclosure: P. Morris: Dr Patrick Morris; Honouraria GSK and Nordic. All other authors have declared no conflicts of interest.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdu356.66</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv538-iv538</ispartof><rights>European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>O'Brien, M.M.</creatorcontrib><creatorcontrib>Pfeiffer, E.M.</creatorcontrib><creatorcontrib>Yen, D.</creatorcontrib><creatorcontrib>Keenan, L.</creatorcontrib><creatorcontrib>McHugh, J.</creatorcontrib><creatorcontrib>Doyle, P.</creatorcontrib><creatorcontrib>Doherty, M.</creatorcontrib><creatorcontrib>O'Reilly, A.</creatorcontrib><creatorcontrib>Hennessy, B.</creatorcontrib><creatorcontrib>Williams, D.</creatorcontrib><creatorcontrib>Horgan, A.M.</creatorcontrib><creatorcontrib>Breathnach, O.S.</creatorcontrib><creatorcontrib>Grogan, W.M.</creatorcontrib><creatorcontrib>Morris, P.</creatorcontrib><title>1546PASSESSMENT OF OLDER PATIENTS WITH CANCER: EDMONTON FRAIL SCALE (EFS) AS A PREDICTOR OF ADVERSE OUTCOMES IN A COHORT OF OLDER PATIENTS UNDERGOING SYSTEMIC THERAPY</title><title>Annals of oncology</title><description>Abstract
Aim: Older cancer patients (pts) are at risk of toxicity from systemic therapy (ST). The EFS is a geriatric tool assessing frailty covering: Cognition, Health, Independence, Performance, Social, Medications, Nutrition, Mood, and Continence. It is unknown if the EFS can predict toxicity in pts who have already been selected for ST. Prospectively we examined the EFS as a predictor of adverse outcomes in older pts undergoing ST.
Methods: Candidates seen by a Medical Oncologist and deemed appropriate for ST ≥65years, starting new ST were included. EFS, demographics, diagnosis, ECOG performance status (PS) and adverse events using the NCI CTCAE v4.03 were assessed. The association between EFS and toxicity was examined during one treatment cycle using Pearson's correlation coefficient (r).
Results: From Feb-April 2014, 24 pts were included (table), median age 72 years (65–92). EFS results were; No frailty 10 (42%), Apparently vulnerable 8 (33%), Mild frailty 4 (17%), Moderate frailty 1 (4%) and Severe frailty 1 (4%). Many were of good PS (54% had ECOG 1). All toxicities were recorded with most common non-lab toxicities being fatigue 12 (50%) and pain 8 (33%), all ≤grade III. The most common lab toxicities were Hb and Alk Phos. During ST there were 3 (13%) admissions, 6 (25%) had treatments held or dose adjustments and 1 death occurred. Age and ECOG were significantly correlated (r=0.43, p = <0.04). Age was not associated with toxicity events (r=0.19, p < 0.37). ECOG PS was not associated with total number of toxicities (r=-0.05, p < 0.8). A moderate association between EFS and number of toxicity events was seen (r=0.32), but did not reach statistical significance (p < 0.14). Updated results including toxicity on subsequent ST cycles from an expanded cohort will be presented.
Patient CharacteristicsN%SexMale1042Female1458Marital StatusMarried1042Widowed833Single417Divorced / separated28Work StatusRetired2292Part-time employed14Other14Cancer DiagnosisColorectal625Breast625Other GI313Lung313Genitourinary28Others417StageI-III1250IV1146N/A (Brain)14
Conclusions: Preliminary results suggest elevated EFS score is associated with toxicities during the first cycle of ST. Quantifying frailty could aid formation of a predictive model for adverse events in the geriatric population.
Disclosure: P. Morris: Dr Patrick Morris; Honouraria GSK and Nordic. All other authors have declared no conflicts of interest.</description><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqVkE1LxDAYhIMoWD_uHt-jIt1Ntm203kL6dhtok5JklT2F4gcobnfZsgf_kL_TLuvRi6dhhmEGHkKuGJ0wmifTru_X_fN09bJLMj7h_IhELON5fE9Tdkwims-S-C5L0lNyNgwflFKez_KIfLMs5a1wDp1rUHswJZi6QAut8GoMHDwpX4EUWqJ9ACwao73RUFqhanBS1AjXWLobEA4EtBYLJb2x-yFRPKJ1CGbhpWnQgdJjRZrK2L-OFnq0c6P0HNzSeWyUBF-hFe3ygpy8dZ_D6-WvnpPbEr2s4vVuEzbb91W3_QqMhj2KcEARDigC58n_2j-4cFue</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>O'Brien, M.M.</creator><creator>Pfeiffer, E.M.</creator><creator>Yen, D.</creator><creator>Keenan, L.</creator><creator>McHugh, J.</creator><creator>Doyle, P.</creator><creator>Doherty, M.</creator><creator>O'Reilly, A.</creator><creator>Hennessy, B.</creator><creator>Williams, D.</creator><creator>Horgan, A.M.</creator><creator>Breathnach, O.S.</creator><creator>Grogan, W.M.</creator><creator>Morris, P.</creator><general>Oxford University Press</general><scope/></search><sort><creationdate>20140901</creationdate><title>1546PASSESSMENT OF OLDER PATIENTS WITH CANCER: EDMONTON FRAIL SCALE (EFS) AS A PREDICTOR OF ADVERSE OUTCOMES IN A COHORT OF OLDER PATIENTS UNDERGOING SYSTEMIC THERAPY</title><author>O'Brien, M.M. ; Pfeiffer, E.M. ; Yen, D. ; Keenan, L. ; McHugh, J. ; Doyle, P. ; Doherty, M. ; O'Reilly, A. ; Hennessy, B. ; Williams, D. ; Horgan, A.M. ; Breathnach, O.S. ; Grogan, W.M. ; Morris, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-oup_primary_10_1093_annonc_mdu356_663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>O'Brien, M.M.</creatorcontrib><creatorcontrib>Pfeiffer, E.M.</creatorcontrib><creatorcontrib>Yen, D.</creatorcontrib><creatorcontrib>Keenan, L.</creatorcontrib><creatorcontrib>McHugh, J.</creatorcontrib><creatorcontrib>Doyle, P.</creatorcontrib><creatorcontrib>Doherty, M.</creatorcontrib><creatorcontrib>O'Reilly, A.</creatorcontrib><creatorcontrib>Hennessy, B.</creatorcontrib><creatorcontrib>Williams, D.</creatorcontrib><creatorcontrib>Horgan, A.M.</creatorcontrib><creatorcontrib>Breathnach, O.S.</creatorcontrib><creatorcontrib>Grogan, W.M.</creatorcontrib><creatorcontrib>Morris, P.</creatorcontrib><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>O'Brien, M.M.</au><au>Pfeiffer, E.M.</au><au>Yen, D.</au><au>Keenan, L.</au><au>McHugh, J.</au><au>Doyle, P.</au><au>Doherty, M.</au><au>O'Reilly, A.</au><au>Hennessy, B.</au><au>Williams, D.</au><au>Horgan, A.M.</au><au>Breathnach, O.S.</au><au>Grogan, W.M.</au><au>Morris, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1546PASSESSMENT OF OLDER PATIENTS WITH CANCER: EDMONTON FRAIL SCALE (EFS) AS A PREDICTOR OF ADVERSE OUTCOMES IN A COHORT OF OLDER PATIENTS UNDERGOING SYSTEMIC THERAPY</atitle><jtitle>Annals of oncology</jtitle><date>2014-09-01</date><risdate>2014</risdate><volume>25</volume><issue>suppl_4</issue><spage>iv538</spage><epage>iv538</epage><pages>iv538-iv538</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Abstract
Aim: Older cancer patients (pts) are at risk of toxicity from systemic therapy (ST). The EFS is a geriatric tool assessing frailty covering: Cognition, Health, Independence, Performance, Social, Medications, Nutrition, Mood, and Continence. It is unknown if the EFS can predict toxicity in pts who have already been selected for ST. Prospectively we examined the EFS as a predictor of adverse outcomes in older pts undergoing ST.
Methods: Candidates seen by a Medical Oncologist and deemed appropriate for ST ≥65years, starting new ST were included. EFS, demographics, diagnosis, ECOG performance status (PS) and adverse events using the NCI CTCAE v4.03 were assessed. The association between EFS and toxicity was examined during one treatment cycle using Pearson's correlation coefficient (r).
Results: From Feb-April 2014, 24 pts were included (table), median age 72 years (65–92). EFS results were; No frailty 10 (42%), Apparently vulnerable 8 (33%), Mild frailty 4 (17%), Moderate frailty 1 (4%) and Severe frailty 1 (4%). Many were of good PS (54% had ECOG 1). All toxicities were recorded with most common non-lab toxicities being fatigue 12 (50%) and pain 8 (33%), all ≤grade III. The most common lab toxicities were Hb and Alk Phos. During ST there were 3 (13%) admissions, 6 (25%) had treatments held or dose adjustments and 1 death occurred. Age and ECOG were significantly correlated (r=0.43, p = <0.04). Age was not associated with toxicity events (r=0.19, p < 0.37). ECOG PS was not associated with total number of toxicities (r=-0.05, p < 0.8). A moderate association between EFS and number of toxicity events was seen (r=0.32), but did not reach statistical significance (p < 0.14). Updated results including toxicity on subsequent ST cycles from an expanded cohort will be presented.
Patient CharacteristicsN%SexMale1042Female1458Marital StatusMarried1042Widowed833Single417Divorced / separated28Work StatusRetired2292Part-time employed14Other14Cancer DiagnosisColorectal625Breast625Other GI313Lung313Genitourinary28Others417StageI-III1250IV1146N/A (Brain)14
Conclusions: Preliminary results suggest elevated EFS score is associated with toxicities during the first cycle of ST. Quantifying frailty could aid formation of a predictive model for adverse events in the geriatric population.
Disclosure: P. Morris: Dr Patrick Morris; Honouraria GSK and Nordic. All other authors have declared no conflicts of interest.</abstract><pub>Oxford University Press</pub><doi>10.1093/annonc/mdu356.66</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv538-iv538 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_oup_primary_10_1093_annonc_mdu356_66 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | 1546PASSESSMENT OF OLDER PATIENTS WITH CANCER: EDMONTON FRAIL SCALE (EFS) AS A PREDICTOR OF ADVERSE OUTCOMES IN A COHORT OF OLDER PATIENTS UNDERGOING SYSTEMIC THERAPY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T00%3A58%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1546PASSESSMENT%20OF%20OLDER%20PATIENTS%20WITH%20CANCER:%20EDMONTON%20FRAIL%20SCALE%20(EFS)%20AS%20A%20PREDICTOR%20OF%20ADVERSE%20OUTCOMES%20IN%20A%20COHORT%20OF%20OLDER%20PATIENTS%20UNDERGOING%20SYSTEMIC%20THERAPY&rft.jtitle=Annals%20of%20oncology&rft.au=O'Brien,%20M.M.&rft.date=2014-09-01&rft.volume=25&rft.issue=suppl_4&rft.spage=iv538&rft.epage=iv538&rft.pages=iv538-iv538&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdu356.66&rft_dat=%3Coup%3E10.1093/annonc/mdu356.66%3C/oup%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/annonc/mdu356.66&rfr_iscdi=true |